COSMNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31
Cosmos Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026
$0.33−0.01 (-1.90%)
Close on Oct 19, 2026
- Market cap
- $19.48M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
12.1%−2.5 pts over 5 years
Operating margin
-25.6%−30.5 pts over 5 years
Net margin
-29.3%−30.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +19.9% | +9.0% | +3.3% | +61.7% | |
| Gross profit | +83.1% | +9.8% | -0.4% | +66.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 40.1% | -15.5% | -89.1% | |
| Return on assets | -31.8% | 2.4% | -32.0% | |
| Current ratio | 0.54 | 1.19 | 1.00 | |
| Debt to equity | – | -2.59 | 0.09 | |
| Net debt to EBITDA | – | 3.26× | -0.06× | |
| Interest coverage | -1.1× | 1.0× | -8.8× | |
| Inventory turnover | – | 14.0× | 11.3× | |
| Capex to revenue | 0.2% | 0.2% | 0.1% | |
| Diluted shares | 1M | 1M | 30M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cosmos Health generated $53.77M from operations and spent $2.92M on capital expenditure, dividends and share buybacks. 84% of that went back into the business.
Generated
$53.77M
Used
$2.92M
Capital expenditure$2.44M84%Dividends$00%Share buybacks$477.32K16%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-29.3%
×Asset turnover1.09×
×Equity multiplier2.79×
=Return on equity, FY2025-89.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -29.3% | 1.09× | 2.79× | -89.1% |
| FY2024 | -29.7% | 0.90× | 1.99× | -53.4% |
| FY2023 | -34.7% | 0.80× | 1.78× | -49.2% |
| FY2022 | -27.5% | 0.86× | 2.69× | -63.3% |
| FY2021 | -14.2% | 1.21× | 426.98× | -7289.2% |
| FY2020 | 1.5% | 1.64× | -6.38× | -15.5% |
| FY2019 | -8.3% | 1.78× | -4.56× | 67.5% |
| FY2018 | -24.4% | 2.36× | -4.94× | 285.6% |
| FY2017 | -20.7% | 4.35× | -2.89× | 259.8% |
| FY2016 | -8.9% | 3.58× | -1.26× | 40.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$19.14M
- Cash generatingOperating cash flow above zero-$8.45M
- Return on assets improvedROA up on the prior year-24.5% → -35.3%
- Earnings backed by cashOperating cash flow above net income-$8.45M vs -$19.14M
- Less leverageLong-term debt to assets fell2.9% → 2.4%
- Better liquidityCurrent ratio rose0.99 → 1.00
- No dilutionShare count did not rise19M → 30M
- Gross margin improvedGross margin up on the prior year7.92% → 12.10%
- More efficientAsset turnover rose0.82 → 1.20